Article ID Journal Published Year Pages File Type
3272405 Journal de Gynécologie Obstétrique et Biologie de la Reproduction 2014 9 Pages PDF
Abstract
To perform papsmear before 25 years because the patient has associated high risk HPV co-factors does not appear justified by the severity or frequency of cytological lesions, especially as it increases the financial cost and is responsible of potential deleterious actions such as conizations probably excessive among the youngest patients. Personalized monitoring of these patients with a pathological papsmear is required. The French practice recommendations on cervical cancer screening (first screening at age 25, 26 years cytological control then every 3 years up to 65 years in patients who have or have had sex) deserve to be applied in young and disadvantaged patients.
Related Topics
Health Sciences Medicine and Dentistry Endocrinology, Diabetes and Metabolism
Authors
, , , , , , , ,